{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:01:05Z","timestamp":1791489665240,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":256,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005283","name":"FUNCAP","doi-asserted-by":"publisher","award":["ITR-00214-00056.01.00\/23"],"award-info":[{"award-number":["ITR-00214-00056.01.00\/23"]}],"id":[{"id":"10.13039\/501100005283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101444","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:31:29Z","timestamp":1789821089000},"page":"101444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohort"],"prefix":"10.1016","volume":"49","author":[{"given":"Juliana Cordeiro","family":"de Sousa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleto","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme de Sousa","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emerson Lucena","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marclesson Santos","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Martins Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Pereira","family":"Ornellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2361-0613","authenticated-orcid":false,"given":"Fabio","family":"Tavora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101444_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced non-small-cell lung cancer","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101444_bib0002","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1111\/1759-7714.14156","article-title":"Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations","volume":"12","author":"Li","year":"2021","journal-title":"Thorac. Cancer"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101444_bib0003","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101444_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646577","article-title":"The predictive values of advanced non-small cell lung cancer patients harboring uncommon EGFR mutations\u2014the mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations","volume":"11","author":"Tan","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101444_bib0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21147\/j.issn.1000-9604.2017.01.03","article-title":"Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations","volume":"29","author":"Zhang","year":"2017","journal-title":"Chin. J. Cancer Res."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101444_bib0006","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41598-019-39965-x","article-title":"Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations","volume":"9","author":"Leal","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101444_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s42047-026-00216-9","article-title":"EGFR variant profiles in lung adenocarcinoma from different regions of Brazil: a multi-institutional study using a rapid RT-PCR platform","volume":"9","author":"de Andrade Natal","year":"2026","journal-title":"Surg. Exp. Pathol."},{"key":"10.1016\/j.ctarc.2026.101444_bib0008","article-title":"Molecular characterization of non-small cell lung cancer tumors in Latin American patients from Brazil, Chile and Peru uncovers novel potentially driver mutations","author":"Sep\u00falveda-Hermosilla","year":"2020","journal-title":"MedRxiv"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101444_bib0009","doi-asserted-by":"crossref","first-page":"e1419","DOI":"10.1093\/oncolo\/oyae129","article-title":"Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies","volume":"29","author":"Cavagna","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101444_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101444_bib0011","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.21037\/apm-21-2828","article-title":"Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations (excluding primary T790M mutation)","volume":"11","author":"Si","year":"2022","journal-title":"Ann. Palliat. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101444_bib0012","article-title":"Navigating the treatment landscape of uncommon EGFR mutations in non-small cell lung cancer","volume":"16","author":"Trinh","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101444_bib0013","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, 3, and 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol."},{"issue":"7878","key":"10.1016\/j.ctarc.2026.101444_bib0014","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101444_bib0015","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2011.38.3224","article-title":"Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer","volume":"30","author":"Su","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101444_bib0016","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","article-title":"Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors","volume":"23","author":"Canale","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101444_bib0017","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101444_bib0018","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer: a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101444_bib0019","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101444_bib0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"30","key":"10.1016\/j.ctarc.2026.101444_bib0021","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101444_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/1878-0261.13327","article-title":"Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasets","volume":"17","author":"Viteri","year":"2022","journal-title":"Mol. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:43:10Z","timestamp":1791488590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"alternative-id":["S2468294226003540"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101444","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond Exons 19 and 21: mapping the clinical and molecular diversity of uncommon EGFR mutations in a Brazilian NSCLC cohort","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101444"}}